Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2021 - 2025)

Alnylam Pharmaceuticals' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at -$680000.0 for Q4 2025.

• Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$680000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $253.3 million (down 75.07% YoY) and the FY2025 annual result came in at $645.7 million, changed N/A from the prior year.
• Long-Term Debt Issuances was -$680000.0 for Q4 2025 at Alnylam Pharmaceuticals, down from $254.0 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $762.1 million in Q3 2022 and bottomed at -$250.0 million in Q3 2021.
• A 3-year average of $191.4 million and a median of $126.7 million in 2022 frame the typical range for Long-Term Debt Issuances.
• Peak annual rise in Long-Term Debt Issuances reached 404.84% in 2022, while the deepest fall reached 404.84% in 2022.
• Alnylam Pharmaceuticals' Long-Term Debt Issuances stood at -$250.0 million in 2021, then soared by 201.6% to $254.0 million in 2022, then plunged by 100.27% to -$680000.0 in 2025.
• Business Quant data shows ALNY's Long-Term Debt Issuances at -$680000.0 in Q4 2025, $254.0 million in Q4 2022, and $762.1 million in Q3 2022.